Are Analysts Bullish Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) After Last Week?

February 12, 2018 - By Peter Erickson

 Are Analysts Bullish Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) After Last Week?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Ratings Coverage

Among 7 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals had 15 analyst reports since July 22, 2015 according to SRatingsIntel. The company was initiated on Wednesday, July 22 by Roth Capital. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, December 20. Oppenheimer initiated Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) rating on Tuesday, July 28. Oppenheimer has “Outperform” rating and $8 target. The firm has “Buy” rating given on Wednesday, July 22 by TH Capital. The rating was initiated by H.C. Wainwright with “Buy” on Tuesday, May 30. The firm has “Buy” rating given on Wednesday, October 18 by H.C. Wainwright. JMP Securities initiated the stock with “Market Outperform” rating in Wednesday, August 12 report. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 11 report. H.C. Wainwright maintained it with “Buy” rating and $9.0 target in Friday, November 10 report. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. Below is a list of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) latest ratings and price target changes.

17/01/2018 Broker: William Blair Rating: Outperform Initiates Coverage On
20/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
10/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
17/08/2017 Broker: Oppenheimer Rating: Buy New Target: $9.0 Maintain

The stock increased 4.42% or $0.38 during the last trading session, reaching $8.97. About 1.34 million shares traded or 128.08% up from the average. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 128.81% since February 12, 2017 and is uptrending. It has outperformed by 112.11% the S&P500.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $401.81 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.

More notable recent Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) news were published by: Businesswire.com which released: “Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno …” on February 09, 2018, also Benzinga.com with their article: “44 Biggest Movers From Friday” published on February 12, 2018, Marketwired.com published: “Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th” on January 29, 2018. More interesting news about Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) were released by: Seekingalpha.com and their article: “Biotech Forum Daily Digest For February 12th” published on February 12, 2018 as well as Seekingalpha.com‘s news article titled: “Pieris Pharmaceuticals: Management Continues To Execute” with publication date: February 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: